Funding for this research was provided by:
Doris Duke Charitable Foundation (2019104)
Global Blood Therapeutics
Novartis Pharmaceuticals Corporation
Received: 27 April 2021
Accepted: 24 September 2021
First Online: 19 October 2021
: The study protocol was reviewed by Advarra and received an exempt determination. Using the Department of Health and Human Services regulations found at 45 CFR 46.104(d)(2), the IRB determined that the project is exempt from IRB oversight. The IRB also completed the necessary additional limited review considerations as set forth under the Revised Common Rule, 45 CFR 46.104(d).
: Not applicable.
: The authors declare that they have no competing interests.